Drug Profile

ANX 105

Alternative Names: ANX-105

Latest Information Update: 28 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Annexon
Class Monoclonal antibodies
Mechanism of Action Complement C1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Autoimmune disorders
No development reported Neurodegenerative disorders

Most Recent Events

28 Mar 2025 No recent reports of development identified for phase-I development in Neurodegenerative-disorders(In volunteers) in Netherlands (IV, Infusion)
01 Oct 2022 Phase-I clinical trials in Autoimmune disorders in USA (IV) (Annexon pipeline, October 2022)
09 May 2022 Dutch regulatory authorities clear the Clinical Trial Application (CTA) for ANX 105 in Neurodegenerative disorders

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com